Plasma Apelin and Asymmetric Dimethylarginine (ADMA) Levels Shortly After Laparoscopic Greater Curvature Plication

[1] Guh DP(2009)The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis BMC Public Health 9 88-327

[2] Zhang W(2014)Trends in the prevalence of diabetes and impaired fasting glucose in association with obesity in Iran: 2005–2011 Diabetes Res Clin Pract 103 319-880

[3] Bansback N(2015)Parathyroid hormone levels may predict nonalcoholic steatohepatitis in morbidly obese patients Hepat Mon 15 e29697-355

[4] Amarsi Z(2006)Mechanisms linking obesity with cardiovascular disease Nature 444 875-SS2

[5] Birmingham CL(2004)Adipokines: inflammation and the pleiotropic role of white adipose tissue Br J Nutr 92 347-228

[6] Anis AH(1992)Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis J Cardiovasc Pharmacol 20 S60-658

[7] Esteghamati A(2011)Elevated concentration of asymmetric dimethylarginine (ADMA) in individuals with metabolic syndrome Nitric oxide : biology and chemistry / official journal of the Nitric Oxide Society 24 224-1847

[8] Etemad K(1999)Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension J Cardiovasc Pharmacol 33 652-1203

[9] Koohpayehzadeh J(1998)Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia Circulation 98 1842-575

[10] Abbasi M(2001)Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus Am J Cardiol 88 1201-6281

[1] Guh DP(2009)The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis BMC Public Health 9 88-327

[2] Zhang W(2014)Trends in the prevalence of diabetes and impaired fasting glucose in association with obesity in Iran: 2005–2011 Diabetes Res Clin Pract 103 319-880

[3] Bansback N(2015)Parathyroid hormone levels may predict nonalcoholic steatohepatitis in morbidly obese patients Hepat Mon 15 e29697-355

[4] Amarsi Z(2006)Mechanisms linking obesity with cardiovascular disease Nature 444 875-SS2

[5] Birmingham CL(2004)Adipokines: inflammation and the pleiotropic role of white adipose tissue Br J Nutr 92 347-228

[6] Anis AH(1992)Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis J Cardiovasc Pharmacol 20 S60-658

[7] Esteghamati A(2011)Elevated concentration of asymmetric dimethylarginine (ADMA) in individuals with metabolic syndrome Nitric oxide : biology and chemistry / official journal of the Nitric Oxide Society 24 224-1847

[8] Etemad K(1999)Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension J Cardiovasc Pharmacol 33 652-1203

[9] Koohpayehzadeh J(1998)Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia Circulation 98 1842-575

[10] Abbasi M(2001)Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus Am J Cardiol 88 1201-6281